Compare Stocks: LYRA, CPMD, SXTC, and ATXI

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATXI Avenue Therapeutics	$0.41 +13.2%	$0.42	$0.15 ▼ $0.97	$1.34M	-0.23	6,942 shs	1,082 shs
CPMD Golden Dragon	$0.00	$0.00	$0.00 ▼ $0.01	$1.41M	2.36	40,753 shs	28,340 shs
LYRA Lyra Therapeutics	$0.15 +400.0%	$0.22	$0.00 ▼ $8.75	$270K	0.5	482 shs	348 shs
SXTC China SXT Pharmaceuticals	$2.41 -18.6%	$3.44	$1.78 ▼ $83,758.80	$1.41M	1.86	843,959 shs	778,068 shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATXI Avenue Therapeutics	+1.90%	-18.48%	-28.49%	+33.64%	-43.39%
CPMD Golden Dragon	0.00%	0.00%	-16.67%	-13.04%	-33.33%
LYRA Lyra Therapeutics	0.00%	-25.00%	-25.00%	-78.85%	-97.74%
SXTC China SXT Pharmaceuticals	-18.58%	-6.23%	+8.56%	-98.77%	-99.99%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATXI Avenue Therapeutics	$0.41 +13.2%	$0.42	$0.15 ▼ $0.97	$1.34M	-0.23	6,942 shs	1,082 shs
CPMD Golden Dragon	$0.00	$0.00	$0.00 ▼ $0.01	$1.41M	2.36	40,753 shs	28,340 shs
LYRA Lyra Therapeutics	$0.15 +400.0%	$0.22	$0.00 ▼ $8.75	$270K	0.5	482 shs	348 shs
SXTC China SXT Pharmaceuticals	$2.41 -18.6%	$3.44	$1.78 ▼ $83,758.80	$1.41M	1.86	843,959 shs	778,068 shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATXI Avenue Therapeutics	+1.90%	-18.48%	-28.49%	+33.64%	-43.39%
CPMD Golden Dragon	0.00%	0.00%	-16.67%	-13.04%	-33.33%
LYRA Lyra Therapeutics	0.00%	-25.00%	-25.00%	-78.85%	-97.74%
SXTC China SXT Pharmaceuticals	-18.58%	-6.23%	+8.56%	-98.77%	-99.99%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATXI Avenue Therapeutics	0.00	N/A	N/A	N/A
CPMD Golden Dragon	0.00	N/A	N/A	N/A
LYRA Lyra Therapeutics	1.00	Sell	N/A	N/A
SXTC China SXT Pharmaceuticals	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest LYRA, CPMD, SXTC, and ATXI Analyst Ratings

Date	Company	Brokerage	Action	Rating
9/16/2026	SXTC China SXT Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E) ➝ Sell (E+)
8/31/2026	SXTC China SXT Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (E+) ➝ Sell (E)
8/11/2026	SXTC China SXT Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E) ➝ Sell (E+)
7/28/2026	SXTC China SXT Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (E+) ➝ Sell (E)
7/10/2026	SXTC China SXT Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E) ➝ Sell (E+)

(Data available from 10/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATXI Avenue Therapeutics	N/A	N/A	N/A	N/A	$1.92 per share	N/A
CPMD Golden Dragon	$1.36M	1.04	N/A	N/A	($0.05) per share	-0.04
LYRA Lyra Therapeutics	$400K	0.66	N/A	N/A	($6.04) per share	-0.02
SXTC China SXT Pharmaceuticals	$1.14M	1.01	N/A	N/A	$2,468.59 per share	0.00

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATXI Avenue Therapeutics	-$10.38M	-$0.85	0.02	N/A	N/A	N/A	-471.57%	-296.50%	11/13/2026 (Estimated)
CPMD Golden Dragon	-$11.13M	-$0.01	N/A	N/A	N/A	-666.22%	N/A	-141.01%	N/A
LYRA Lyra Therapeutics	-$28.92M	-$19.15	N/A	N/A	N/A	N/A	N/A	N/A	11/17/2026 (Estimated)
SXTC China SXT Pharmaceuticals	-$6.20M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATXI Avenue Therapeutics	N/A	N/A	N/A	N/A	N/A
CPMD Golden Dragon	N/A	N/A	N/A	N/A	N/A
LYRA Lyra Therapeutics	N/A	N/A	N/A	N/A	N/A
SXTC China SXT Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATXI Avenue Therapeutics	N/A	2.70	2.70
CPMD Golden Dragon	N/A	0.04	N/A
LYRA Lyra Therapeutics	N/A	N/A	N/A
SXTC China SXT Pharmaceuticals	0.02	7.94	7.76

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATXI Avenue Therapeutics	17.34%
CPMD Golden Dragon	N/A
LYRA Lyra Therapeutics	95.62%
SXTC China SXT Pharmaceuticals	5.02%

Insider Ownership

Company	Insider Ownership
ATXI Avenue Therapeutics	8.60%
CPMD Golden Dragon	1.27%
LYRA Lyra Therapeutics	3.25%
SXTC China SXT Pharmaceuticals	3.95%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATXI Avenue Therapeutics	4	3.30 million	2.02 million	Not Optionable
CPMD Golden Dragon	4	706.82 million	697.84 million	Not Optionable
LYRA Lyra Therapeutics	27	1.77 million	1.72 million	No Data
SXTC China SXT Pharmaceuticals	56	478,000	459,000	Not Optionable

LYRA, CPMD, SXTC, and ATXI Headlines

Recent News About These Companies

China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) Short Interest Update

September 26, 2026 | americanbankingnews.com

China SXT Pharmaceuticals, Inc. Announces Share Consolidation

August 5, 2026 | globenewswire.com

Univest Securities, LLC Announces Closing of $9 Million Registered Direct Offering for its Client China SXT Pharmaceuticals Inc. (NASDAQ: SXTC)

July 24, 2026 | globenewswire.com

China SXT Pharmaceuticals Raises $9 Million in Registered Direct Offering

July 24, 2026 | tipranks.com

China SXT Pharmaceuticals Enters $9 Million Registered Direct Offering of Units to Institutional Investors

July 23, 2026 | quiverquant.comQ

China SXT Pharmaceuticals Inc. Announces $9 Million Registered Direct Offering

July 23, 2026 | globenewswire.com

China SXT Pharmaceuticals Inc. Cl A

July 14, 2026 | barrons.com

China SXT Pharmaceuticals shares surge over 25% after hours: Here's why

June 2, 2026 | msn.com

China SXT Pharmaceuticals Launches $100 Million ATM Equity Program with Univest Securities

June 1, 2026 | tipranks.com

China SXT Pharmaceuticals Raises $3.5 Million in Offshore Private Placement

May 11, 2026 | theglobeandmail.com

China Sxt Pharmaceuticals, Inc. Class A

April 7, 2026 | edition.cnn.com

China SXT Pharmaceuticals, Inc. Announces Share Re-classification

March 23, 2026 | globenewswire.com

This nano-cap pharma stock crashed 30% today – what triggered the sell-off?

January 30, 2026 | msn.com

China SXT Pharmaceuticals, Inc. Announces Share Consolidation

January 30, 2026 | globenewswire.com

CHINA SXT PHARMACEUTICALS, INC. ANNOUNCES STRATEGIC INITIATIVE TO APPLY AI TECHNOLOGY ACROSS THE TCM SUPPLY CHAIN

January 15, 2026 | finance.yahoo.com

Univest Securities, LLC Announces Closing of $10 Million Registered Direct Offering for its Client China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC)

January 13, 2026 | globenewswire.com

Why China SXT Pharmaceuticals, Inc.’s (SXTC) Stock Is Down 8.81%

January 11, 2026 | aaii.comA

China SXT Pharmaceuticals Inc. Announces $10 Million Registered Direct Offering

January 9, 2026 | globenewswire.com

CHINA SXT PHARMACEUTICALS, INC. ANNOUNCES STRATEGIC AI INSIGHTS INITIATIVE TO OPTIMIZE TRADITIONAL CHINESE MEDICINE PORTFOLIO, ENHANCE MARKET ANALYSIS AND ...

January 8, 2026 | markets.businessinsider.com

Why China SXT Pharmaceuticals, Inc.’s (SXTC) Stock Is Up 6.88%

January 3, 2026 | aaii.comA

New MarketBeat Followers Over Time

Media Sentiment Over Time

LYRA, CPMD, SXTC, and ATXI Company Descriptions

Avenue Therapeutics NASDAQ:ATXI

$0.41 +0.05 (+13.22%)

As of 10/2/2026 11:06 AM Eastern

Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is based in Bay Harbor Islands, Florida.

Golden Dragon OTCMKTS:CPMD

$0.0020 0.00 (0.00%)

As of 10/2/2026 02:23 PM Eastern

CannaPharmaRX, Inc. operates in the cannabis industry in Canada. It evaluates, negotiates, acquires, and develops various cannabis cultivation projects. The company was incorporated in 1998 and is based in Calgary, Canada.

Lyra Therapeutics OTCMKTS:LYRA

$0.15 +0.12 (+400.00%)

As of 10/2/2026 09:30 AM Eastern

Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase III clinical trial; and LYR-220 for CRS patients with and without nasal polyps. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.

China SXT Pharmaceuticals NASDAQ:SXTC

$2.41 -0.55 (-18.58%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$2.36 -0.05 (-2.07%)

As of 10/2/2026 07:59 PM Eastern

China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers advanced, fine, and regular TCMP products, and raw medicinal material, such as ChenXiang, SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen. It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. The company had an end-customer base of pharmaceutical companies, chain pharmacies, and hospitals in 10 provinces and municipalities in China. China SXT Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Taizhou, China.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LYRA, CPMD, SXTC, and ATXI Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LYRA, CPMD, SXTC, and ATXI Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

LYRA, CPMD, SXTC, and ATXI Company Descriptions

Avenue Therapeutics NASDAQ:ATXI

Golden Dragon OTCMKTS:CPMD

Lyra Therapeutics OTCMKTS:LYRA

China SXT Pharmaceuticals NASDAQ:SXTC

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LYRA, CPMD, SXTC, and ATXI Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LYRA, CPMD, SXTC, and ATXI Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

LYRA, CPMD, SXTC, and ATXI Company Descriptions

Avenue Therapeutics NASDAQ:ATXI

Golden Dragon OTCMKTS:CPMD

Lyra Therapeutics OTCMKTS:LYRA

China SXT Pharmaceuticals NASDAQ:SXTC

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools